Asset
RASDEGAFUSP ALFA
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00948961 | phase1_2 | completed | 2009-09-01 | 2012-06-01 | Celldex Therapeutics | A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 |
| NCT02413827 | phase1_2 | terminated | 2015-04-01 | 2016-11-02 | Celldex Therapeutics | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma |
FDA applications (0)
This company has no applications containing this asset.